$AMBA
AMBARELLA INC

2021 Q3 Form 10-Q Financial Statement

#000156459021047305 Filed on September 08, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3
Revenue $79.33M $50.11M
YoY Change 58.3% -11.16%
Cost Of Revenue $29.91M $19.20M
YoY Change 55.77% -19.91%
Gross Profit $49.42M $31.00M
YoY Change 59.42% -4.43%
Gross Profit Margin 62.3% 61.86%
Selling, General & Admin $15.82M $13.40M
YoY Change 18.07% 7.85%
% of Gross Profit 32.01% 43.23%
Research & Development $39.56M $33.50M
YoY Change 18.08% 10.12%
% of Gross Profit 80.05% 108.06%
Depreciation & Amortization $2.920M $600.0K
YoY Change 386.67% -14.29%
% of Gross Profit 5.91% 1.94%
Operating Expenses $55.38M $46.90M
YoY Change 18.08% 9.46%
Operating Profit -$5.960M -$15.90M
YoY Change -62.52% 52.77%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $218.0K $1.300M
YoY Change -83.23% -40.77%
Pretax Income -$5.742M -$14.01M
YoY Change -59.01% 70.57%
Income Tax $1.400M $700.0K
% Of Pretax Income
Net Earnings -$7.156M -$14.76M
YoY Change -51.5% 44.79%
Net Earnings / Revenue -9.02% -29.45%
Basic Earnings Per Share -$0.20 -$0.43
Diluted Earnings Per Share -$0.20 -$0.43
COMMON SHARES
Basic Shares Outstanding 36.44M 34.48M
Diluted Shares Outstanding 36.44M 34.48M

Balance Sheet

Concept 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $449.2M $410.7M
YoY Change 9.36% 9.29%
Cash & Equivalents $258.4M $220.6M
Short-Term Investments $190.8M $190.1M
Other Short-Term Assets $4.491M $3.500M
YoY Change 28.31% -22.22%
Inventory $42.08M $23.91M
Prepaid Expenses
Receivables $38.30M $23.30M
Other Receivables $0.00 $0.00
Total Short-Term Assets $534.0M $461.4M
YoY Change 15.74% 8.41%
LONG-TERM ASSETS
Property, Plant & Equipment $18.30M $5.027M
YoY Change 264.09% -17.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $15.33M $15.60M
YoY Change -1.71% 197.37%
Total Long-Term Assets $76.04M $72.00M
YoY Change 5.61% 11.43%
TOTAL ASSETS
Total Short-Term Assets $534.0M $461.4M
Total Long-Term Assets $76.04M $72.00M
Total Assets $610.1M $533.4M
YoY Change 14.37% 8.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $33.12M $13.70M
YoY Change 141.72% -27.56%
Accrued Expenses $49.79M $35.60M
YoY Change 39.87% 33.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $85.54M $51.20M
YoY Change 67.06% 8.38%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $13.71M $16.68M
YoY Change -17.83% 76.84%
Total Long-Term Liabilities $13.71M $16.68M
YoY Change -17.83% 76.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $85.54M $51.20M
Total Long-Term Liabilities $13.71M $16.68M
Total Liabilities $107.0M $74.80M
YoY Change 43.05% 21.09%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $503.1M $458.6M
YoY Change
Total Liabilities & Shareholders Equity $610.1M $533.4M
YoY Change 14.37% 8.81%

Cashflow Statement

Concept 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$7.156M -$14.76M
YoY Change -51.5% 44.79%
Depreciation, Depletion And Amortization $2.920M $600.0K
YoY Change 386.67% -14.29%
Cash From Operating Activities $14.44M -$2.400M
YoY Change -701.54% -129.63%
INVESTING ACTIVITIES
Capital Expenditures -$1.800M -$300.0K
YoY Change 500.0% -40.0%
Acquisitions
YoY Change
Other Investing Activities $15.94M -$14.20M
YoY Change -212.26% -254.35%
Cash From Investing Activities $14.14M -$14.40M
YoY Change -198.2% -263.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.315M 900.0K
YoY Change 157.22% -40.0%
NET CHANGE
Cash From Operating Activities 14.44M -2.400M
Cash From Investing Activities 14.14M -14.40M
Cash From Financing Activities 2.315M 900.0K
Net Change In Cash 30.89M -15.90M
YoY Change -294.3% -186.41%
FREE CASH FLOW
Cash From Operating Activities $14.44M -$2.400M
Capital Expenditures -$1.800M -$300.0K
Free Cash Flow $16.24M -$2.100M
YoY Change -873.19% -124.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y9M25D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y7D
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17639000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-7156000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
503054000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-184000
CY2020Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1000000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-435000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-329000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-619000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2144000
amba Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1763000
amba Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1031000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
3754000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
665000
amba Payment For Intangible Asset
PaymentForIntangibleAsset
2288000
amba Capital Expenditures Incurred But Not Yet Paid And Financing Incurred For Tangible And Intangible Asset Purchased
CapitalExpendituresIncurredButNotYetPaidAndFinancingIncurredForTangibleAndIntangibleAssetPurchased
1174000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reported periods. Actual results could differ from those estimates.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On an ongoing basis, management evaluates its estimates and assumptions, including those related to (i) write down of excess and obsolete inventories; (ii) the estimated useful lives of long-lived assets; (iii) the valuation of stock-based compensation awards and financial instruments; (iv) the probability of performance objectives achievement; and (v) the realization of tax assets and estimates of tax liabilities, including reserves for uncertain tax positions. These estimates and assumptions are based on historical experience and on various other factors which the Company believes to be reasonable under the circumstances. The Company may engage third-party valuation specialists to assist with estimates related to the valuation of financial instruments, assets and stock awards associated with various contractual arrangements. Such estimates often require the selection of appropriate valuation methodologies and significant judgment. Actual results could differ from these estimates under different assumptions or circumstances and such differences could be material. </p> <p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> also assessed the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">impacts </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the above accounting matters as of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2021</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and through the date of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issuing </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">this report. While </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it is difficult to quantify the impact of COVID-19</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the future </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">magnitude and duration of COVID-19, as well as other </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">associated </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">factors, could r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">esult in material negative impacts to the Company’s </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condensed consolidated financial statements</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in future reporting periods</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
231403000
CY2020Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
9000
us-gaap Inventory Write Down
InventoryWriteDown
0
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
632000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
24000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
215041000
CY2021Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
213583000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1226000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
7000
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
214802000
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
214802000
CY2021Q3 amba Liabilities Associated With Noncancelable Internal Use Software License At Net Present Value Current
LiabilitiesAssociatedWithNoncancelableInternalUseSoftwareLicenseAtNetPresentValueCurrent
5600000
CY2021Q3 amba Liabilities Associated With Noncancelable Internal Use Software License At Net Present Value Noncurrent
LiabilitiesAssociatedWithNoncancelableInternalUseSoftwareLicenseAtNetPresentValueNoncurrent
3000000.0
CY2021Q1 amba Available For Sale Securities Debt Maturities Within One Year
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYear
135899000
CY2021Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
25211000
CY2021Q1 amba Available For Sale Securities Debt Maturities Within One To Three Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneToThreeYearsFairValue
78903000
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
214802000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
215041000
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
214802000
CY2021Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
18219000
CY2021Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7862000
CY2021Q1 us-gaap Inventory Net
InventoryNet
26081000
us-gaap Depreciation
Depreciation
1300000
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22008000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16478000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5530000
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
9411000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
15800000
CY2021Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
25143000
CY2021Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
6440000
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
18703000
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
800000
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
700000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1600000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1400000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
907000
us-gaap Operating Lease Payments
OperatingLeasePayments
1763000
CY2021Q3 amba Lease Liabilities Arising From Obtaining Right Of Use Assets For Operating Lease
LeaseLiabilitiesArisingFromObtainingRightOfUseAssetsForOperatingLease
88000
amba Lease Liabilities Arising From Obtaining Right Of Use Assets For Operating Lease
LeaseLiabilitiesArisingFromObtainingRightOfUseAssetsForOperatingLease
177000
CY2021Q3 amba Leased Assets Obtained In Exchange For Operating Lease Liabilities Arising From Lease Modifications
LeasedAssetsObtainedInExchangeForOperatingLeaseLiabilitiesArisingFromLeaseModifications
0
amba Leased Assets Obtained In Exchange For Operating Lease Liabilities Arising From Lease Modifications
LeasedAssetsObtainedInExchangeForOperatingLeaseLiabilitiesArisingFromLeaseModifications
1687000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y11M26D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0383
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1663000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2917000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2696000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2623000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1178000
CY2021Q3 amba Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
274000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
11351000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
702000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
10649000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
50.28
CY2021Q3 amba Unrecognized Tax Benefits Including Interest
UnrecognizedTaxBenefitsIncludingInterest
9138000
CY2021Q1 amba Unrecognized Tax Benefits Including Interest
UnrecognizedTaxBenefitsIncludingInterest
8966000
CY2021Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1287000
CY2021Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1288000
CY2021Q3 amba Liabilities Associated With Noncancelable Internal Use Software License At Net Present Value Noncurrent
LiabilitiesAssociatedWithNoncancelableInternalUseSoftwareLicenseAtNetPresentValueNoncurrent
2969000
CY2021Q1 amba Liabilities Associated With Noncancelable Internal Use Software License At Net Present Value Noncurrent
LiabilitiesAssociatedWithNoncancelableInternalUseSoftwareLicenseAtNetPresentValueNoncurrent
6259000
CY2021Q3 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
311000
CY2021Q1 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
299000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
13705000
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
16812000
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00045
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00045
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19372000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16394000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
38214000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32430000
CY2021Q3 amba Accrued Share Based Compensation Expense
AccruedShareBasedCompensationExpense
1700000
amba Accrued Share Based Compensation Expense
AccruedShareBasedCompensationExpense
3400000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
719143
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
38.33
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
14700
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
110.19
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
5076
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
56.35
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
35
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
20.15
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
14665000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-14756000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
179188
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
42.83
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
549544
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
46.02
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
29025000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
447533
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
42.41
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
25115000
CY2021Q3 amba Closing Market Price Of Ordinary Shares On Nasdaq On Last Day Of Reporting Period
ClosingMarketPriceOfOrdinarySharesOnNASDAQOnLastDayOfReportingPeriod
98.49
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-7156000
us-gaap Net Income Loss
NetIncomeLoss
-17974000
us-gaap Net Income Loss
NetIncomeLoss
-30219000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36442536
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34480307
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36191420
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34280318
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36442536
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34480307
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36191420
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34280318
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1897540
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2030787
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2067262
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2137555
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14009000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15285000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-28346000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1414000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
747000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2689000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1873000
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.246
CY2020Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.053
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.176
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.066
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5742000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1400000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
700000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2700000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1900000
CY2021Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
27900000
CY2021Q3 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
72300000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
79327000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
50113000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
149460000

Files In Submission

Name View Source Status
0001564590-21-047305-index-headers.html Edgar Link pending
0001564590-21-047305-index.html Edgar Link pending
0001564590-21-047305.txt Edgar Link pending
0001564590-21-047305-xbrl.zip Edgar Link pending
amba-10q_20210731.htm Edgar Link pending
amba-10q_20210731_htm.xml Edgar Link completed
amba-20210731.xsd Edgar Link pending
amba-20210731_cal.xml Edgar Link unprocessable
amba-20210731_def.xml Edgar Link unprocessable
amba-20210731_lab.xml Edgar Link unprocessable
amba-20210731_pre.xml Edgar Link unprocessable
amba-ex102_136.htm Edgar Link pending
amba-ex311_8.htm Edgar Link pending
amba-ex312_6.htm Edgar Link pending
amba-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending